<DOC>
	<DOCNO>NCT01208662</DOCNO>
	<brief_summary>The drug , lenalidomide , bortezomib , dexamethasone , approve FDA . They approve combination multiple myeloma type cancer . Bortezomib currently approve FDA treatment multiple myeloma . Lenalidomide approve use dexamethasone patient multiple myeloma receive least one prior therapy treatment certain type myelodysplastic syndrome ( another type cancer affect blood ) . Dexamethasone commonly use , either alone , combination drug , treat multiple myeloma . Please note Bortezomib Lenalidomide provide patient participate trial charge . Melphalan cyclophosphamide , drug use stem cell collection transplant , also approve FDA . Melphalan FDA-approved chemotherapy multiple myeloma use high-dose conditioning treatment prior stem cell transplantation . Cyclophosphamide use , either alone , combination drug , treat multiple myeloma . These drug use multiple myeloma study information study suggest combination therapy may help treat newly diagnose multiple myeloma . In research study , look explore drug combination , lenalidomide , bortezomib dexamethasone alone combine autologous stem cell transplantation see side effect may well work treatment newly diagnose multiple myeloma . Specifically , objective trial determine , era novel drug , high dose therapy ( HDT ) still necessary initial management multiple myeloma young patient . In study , HDT compare conventional dose treatment would consider superior significantly prolong progression-free survival least 9 month , recognize particular subgroup may benefit compare others .</brief_summary>
	<brief_title>Randomized Trial Lenalidomide , Bortezomib , Dexamethasone vs High-Dose Treatment With SCT MM Patients Age 65</brief_title>
	<detailed_description>After screen procedure determine patient eligible research study , patient randomize one study group : lenalidomide , bortezomib dexamethasone without autologous stem cell transplantation , follow lenalidomide maintenance ( Arm A ) lenalidomide , bortezomib dexamethasone autologous stem cell transplantation , follow lenalidomide maintenance ( Arm B ) . There equal chance place either group . All participant receive one cycle lenalidomide , bortezomib dexamethasone treatment randomize Arm A Arm B . Participants Arm A receive two additional cycle lenalidomide , bortezomib dexamethasone prior stem cell collection . If randomize Arm A , subject undergo stem cell collection , follow five cycle lenalidomide , bortezomib dexamethasone . This follow lenalidomide maintenance treatment disease progression . Participants Arm B receive two additional cycle lenalidomide , bortezomib dexamethasone prior stem cell collection . If randomize Arm B , subject undergo stem cell collection autologous stem cell transplantation , follow two cycle lenalidomide , bortezomib dexamethasone . This follow lenalidomide maintenance treatment disease progression .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Diagnosis Multiple Myeloma , accord International Myeloma Foundation 2003 Diagnostic Criteria Documented symptomatic myeloma , organ damage relate myeloma laboratory assessment perform within 21 day registration Myeloma measurable either serum urine evaluation monoclonal component assay serum free light chain . ECOG performance status &lt; /= 2 Negative HIV blood test Voluntary write informed consent Pregnant lactate female Prior systemic therapy MM ( localize radiotherapy allow least 7 day study entry , corticosteroid allow dose &lt; /= equivalent 160 mg dexamethasone 2 week ) Primary amyloidosis ( AL ) myeloma complicate amylosis Receiving investigational agent Known brain metastasis Poor tolerability allergy study drug compound similar composition Platelet count &lt; 50,000/mm3 , within 21 day registration ANC &lt; 1,000 cells/mm3 , within 21 day registration Hemoglobin &lt; 8 g/dL , within 21 day registration Hepatic impairment ( &gt; /= 1.5 x institutional ULN AST ( SGOT ) , ALT ( SGPT ) , alkaline phosphatase &gt; 2 x ULN ) . Patients benign hyperbilirubinemia eligible . Renal insufficiency ( serum creatinine &gt; 2.0 mg/dl creatinine clearance &lt; 50 ml/min , within 21 day registration ) Respiratory compromise ( DLCO &lt; 50 % ) Clinical sign heart coronary failure LVEF &lt; 40 % . Myocardial infarction within 6 month prior enrollment , NYHA Class III IV heart failure , uncontrolled angina , severe uncontrolled ventricular arrhythmia , electrocardiographic evidence acute ischemia active conductive system abnormality Intercurrent illness include , limited ongoing active severe infection , know infection hepatitis B C virus , poorly control diabetes , severe uncontrolled psychiatric disorder psychiatric illness/social situation would limit compliance study requirement Previous history another malignant condition except basal cell carcinoma stage I cervical cancer . If malignancy experience 2 year ago confirm cure , participant may consider study case case basis PI discussion . Inability comply antithrombotic treatment regimen Peripheral neuropathy &gt; /= Grade 2</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Lenalidomide</keyword>
	<keyword>Bortezomib</keyword>
	<keyword>Dexamethasone</keyword>
	<keyword>Stem Cell Transplant</keyword>
	<keyword>Myeloma</keyword>
	<keyword>Multiple Myeloma</keyword>
</DOC>